throbber
BJU International (1999), 84, 923–947
`
`REVIEW
`
`The pharmacological treatment of urinary incontinence
`K.-E. ANDERSSON, R. APPELL 1 , L.D. CARDOZO2 , C. CHAPPLE 3 , H.P. DRUTZ 4 , A.E. FINKBEINER 5 ,
`F. HAAB 6 and R. VELA NAVARRETE 7
`The Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden, 1Department of Urology, The Cleveland Clinic
`Foundation, Cleveland, Ohio, USA, 2King’s College Hospital, London, UK, 3Department of Urology, Royal Hallamshire Hospital,
`SheBeld, UK, 4Service Urologie, Hopital Tenon University of Toronto, Mount Sinai Hospital, Ontario, Canada, 5Department of
`Urology, University of Arkansas for Medical Sciences, Little Rock, USA, 6Urogynecology Unit, Paris, and 7Department of Urology,
`Universidad Autonoma, Madrid, Spain
`
`Introduction
`The bladder and urethra constitute a functional unit
`which is controlled by a complex interplay between the
`central and peripheral nervous systems and local regulat-
`ory factors [1,2]. Malfunction at various levels may
`result in micturition disorders, which roughly can be
`classified as disturbances of storage or of emptying.
`Failure to store urine may lead to various forms of
`incontinence (mainly urge and stress incontinence), and
`failure to empty can lead to urinary retention, which
`may result in overflow incontinence. Theoretically, a
`disturbed storage function can be improved by agents
`that decrease detrusor activity, increase bladder capacity
`and/or increase outlet resistance. Many drugs have been
`tried, but the results are often disappointing, partly
`through poor treatment eBcacy and side-eCects [3]. The
`development of pharmacological treatment has been
`slow, and the use of some of the currently prescribed
`agents is founded more on tradition than on evidence
`based on results from controlled clinical trials [4–8].
`In the present review of drugs in current use for the
`treatment of urinary incontinence, agents specifically
`used to treat urinary tract infections and interstitial
`cystitis have not been included. The currently used
`terminology conforms with the recommendations of the
`ICS. Drugs have been evaluated using diCerent types of
`evidence (Table 1). Evidence of pharmacological and/or
`physiological eBcacy means that a drug has been shown
`to have desired eCects in relevant preclinical experiments
`or in healthy volunteers (or in experimental situations
`in patients); the present clinical drug recommendations
`are based on evaluations made using a modification of
`the grading of evidence found in the Agency for Health
`Care Policy and Research (AHCPR) guidelines (Table 2).
`
`Accepted for publication 31 August 1999
`
`© 1999 BJU International
`
`Table 1 Types of evidence
`
`Type
`
`Pharmacodynamic
`
`Pharmacokinetic
`
`Physiological
`
`Clinical
`
`Condition
`
`In vitro
`In vivo
`Absorption
`Distribution
`Metabolism
`Excretion
`Animal models
`Clinical phase I
`Trials
`‘practice’
`
`Bladder contraction
`
`Normal bladder contraction in humans is mediated
`mainly through stimulation of muscarinic receptors in
`the detrusor muscle. Atropine resistance, i.e. contraction
`of isolated bladder muscle in response to electrical nerve
`stimulation after pretreatment with atropine, has been
`shown in most animal species, but seems to be of little
`importance in normal human bladder muscle [1].
`However, atropine-resistant
`(nonadrenergic, nonchol-
`inergic, NANC) contractions have been reported in
`normal human detrusor and may be caused by ATP
`[9–11]. A significant degree of atropine resistance may
`exist in morphologically and/or functionally changed
`bladders, and has been reported to occur in hypertrophic
`bladders [12,13], interstitial cystitis [14], and in neuro-
`genic bladders [15]. The importance of the NANC compo-
`nent to detrusor contraction in vivo, normally, and in
`diCerent micturition disorders, remains to be established.
`
`Drugs used to treat bladder hyperactivity
`
`Studies have documented a 33–61% prevalence of an
`overactive bladder in the elderly over the age of 65 years
`
`923
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 1
`
`

`
`924 K.-E. ANDERSSON et al.
`
`Drug
`
`Bladder hyperactivity
`Antimuscarinic drugs
`Atropine, hyoscyamine
`Propantheline
`Emepronium
`Trospium
`Tolterodine
`(Darifenacin)
`Drugs acting on membrane channels
`Calcium antagonists
`Potassium-channel openers
`Drugs with mixed actions
`Oxybutynin
`Dicyclomine
`Propiverine
`Flavoxate
`(Terodiline)
`a-adrenoceptor antagonists
`Alfuzosin
`Doxazosin
`Prazosin
`Terazosin
`Tamsulosin
`b-Adrenoceptor agonists
`Terbutaline
`Clenbuterol
`Salbutamol
`Antidepressants: Imipramine
`Prostaglandin synthesis inhibitors
`Indomethacin
`Flurbiprofen
`Vasopressin analogue: Desmopressin
`Other drugs
`Baclofen
`Capsaicin
`Resiniferatoxin
`Stress incontinence
`a-Adrenoceptor agonists
`Ephedrine
`Norephedrine (phenylpropanolamine)
`Other drugs
`Imipramine
`Clenbuterol
`(Duloxetine)
`Hormones: Oestrogens
`Overflow incontinence
`a-adrenoceptor antagonists
`Alfuzosin
`Doxazosin
`Prazosin
`Terazosin
`Tamsulosin
`(Phenoxybenzamine)
`Muscarinic receptor agonists
`Bethanechol
`
`Evidence*
`
`Pharmacological/
`physiological
`
`Clinical
`
`Assessment
`
`Table 2 Drugs used in the treatment of
`bladder hyperactivity, stress and overflow
`incontinence
`
`E
`E
`E
`E
`E
`Under investigation
`
`C
`A
`A/B
`A
`A
`
`Under investigation
`Under investigation
`
`E
`E
`E
`U
`E
`
`U
`U
`U
`U
`U
`
`U
`U
`U
`E
`
`U
`U
`E
`
`E
`E
`Under investigation
`
`E
`E
`
`A
`B
`A
`B/C
`A
`
`B/C
`B/C
`B/C
`B/C
`B/C
`
`B/C
`B/C
`C
`A
`
`B
`B
`A
`
`C
`B
`
`B/C
`B
`
`U
`U
`Under investigation
`E
`
`C
`B
`
`–
`
`E
`E
`E
`E
`E
`E
`
`E
`
`B
`B
`B
`B
`B
`A/B
`
`B/C
`
`–
`R
`R
`R
`R
`
`R
`–
`R
`–
`–
`
`–
`–
`–
`–
`–
`
`–
`–
`–
`R
`
`–
`–
`R
`
`–
`–
`
`–
`–
`
`–
`–
`
`–
`
`–
`–
`–
`–
`–
`–
`
`–
`
`© 1999 BJU International 84, 923–947
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 2
`
`

`
`Table 2 (Cont’d)
`
`PHARMACOLOGICAL TREATMENT OF URINARY INCONTINENCE
`
`925
`
`Drug
`
`Evidence*
`
`Pharmacological/
`physiological
`
`Carbachol
`Anticholinesterase inhibitor: Distigmine
`Other drugs
`Baclofen
`Benzodiazepines
`Dantrolene
`
`E
`E
`
`E
`E
`E
`
`Clinical
`
`Assessment
`
`B/C
`B/C
`
`B
`C
`C
`
`–
`–
`
`–
`–
`–
`
`*E, eCective; U, unproven; A, good quality RCT; B, clinical studies; C, ‘expert’ opinion;
`R, recommended.
`
`[15–17]. It appears that detrusor hyperactivity may be
`the result of several diCerent mechanisms, both myogenic
`[18] and neurological [19]. Most probably, both factors
`contribute to the genesis of the hyperactive bladder.
`An abundance of drugs has been used for the treat-
`ment of the hyperactive detrusor (Table 2). However, for
`many of them, clinical use is based on the results of
`preliminary, open studies rather than randomized, con-
`trolled clinical trials (RCTs). It should be stressed that in
`many trials on both detrusor instability and detrusor
`hyper-reflexia,
`there has been such a high placebo
`response that meaningful diCerences between placebo
`and active drug cannot be detected. However, drug
`eCects in individual patients may be both useful and
`important.
`
`Antimuscarinic (anticholinergic) drugs
`
`Muscarinic receptors mediate not only normal bladder
`contraction, but also the principal contractions of over-
`active bladders, and antimuscarinic drugs are able to
`produce an almost complete paralysis of the normal
`bladder when injected parenterally. Several studies sug-
`gest that detrusor contractions can also be blocked in
`patients with bladder hyperactivity [20–23]. On the
`other hand, there are several reports of
`insuBcient
`eBcacy for antimuscarinic drugs given orally to patients
`with unstable detrusor contractions [24–27].
`It
`is
`unclear to what extent this can be attributed to low
`bioavailability, side-eCects limiting the dose that can be
`given, or to atropine resistance.
`Atropine and related antimuscarinic drugs are tertiary
`amines. They are well absorbed from the gastrointestinal
`tract and pass easily into the CNS; side-eCects on the CNS
`may therefore limit their use. Quaternary ammonium
`compounds are not well absorbed, pass into the CNS to
`a limited extent, and have a lower incidence of CNS side-
`eCects [28]. They still produce well-known peripheral
`antimuscarinic side-eCects, e.g. accommodation paral-
`
`© 1999 BJU International 84, 923–947
`
`ysis, constipation, tachycardia and dryness of mouth.
`All antimuscarinic drugs are contraindicated in patients
`with narrow-angle glaucoma.
`Antimuscarinic agents are still the most widely used
`treatment for urge and urge incontinence [8]. However,
`currently used drugs lack selectivity for the bladder [29]
`and eCects on other organ systems (Fig. 1) may result
`in side-eCects which limit their usefulness. Theoretically,
`drugs with selectivity for the bladder may be obtained,
`if the receptor subtype(s) mediating bladder contraction,
`and those producing the main side-eCects of antimuscar-
`inic drugs, were diCerent. One way of avoiding many of
`the antimuscarinic side-eCects is to administer the drugs
`intravesically. However, this is practical only in a limited
`number of patients.
`Several subpopulations of muscarinic receptors have
`been identified, and five diCerent subtypes (m1-m5) have
`been cloned. Pharmacologically, five diCerent subtypes
`(M1-M5) have been defined [29–31], all with a wide
`distribution in the body. The subtypes that can be
`detected in the human bladder and those responsible for
`bladder contraction have been studied using various
`approaches. Cultured human detrusor cells expressed M3
`receptors linked to phosphoinositide hydrolysis [32], and
`an important role for M3 receptors is widely accepted
`(Fig. 2). M1, M2, and M3 receptor subtypes were detected
`in human detrusor muscle by receptor binding; there
`was a distinct predominance of M3 receptors [33].
`However, Yamaguchi et al. [34] were able to show the
`presence of mRNA encoding the m2 and m3 subtypes,
`but not the m1, m4 and m5 subtypes in the human
`bladder. Using subtype-specific immunoprecipitation,
`Wang et al. [35] detected only m2 and m3 subtypes in
`human and rabbit detrusor membranes,
`the ratio
`of m25m3 being 351. Despite a predominance of m2
`receptors in the detrusor of several species, it has been
`found that the pharmacologically defined M3 receptor
`mediates bladder contraction [35,36]. However, recently,
`at least in the rat, M2 receptors were also shown to be
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 3
`
`

`
`926 K.-E. ANDERSSON et al.
`
`Fig. 1. The eCects of antimuscarinic drugs
`in diCerent target organs.
`
`able to mediate bladder contraction in vitro as well as in
`vivo by reversing b-adrenoceptor-mediated relaxation
`[37]. What this means for the human bladder is unclear.
`Future studies with muscarinic receptor antagonists
`with a selectivity for M3 receptors, such as darifenacin
`[38,39], vamicamide [40] and zamifenacin [41], will
`reveal whether or not the principle of selective M3
`receptor antagonism oCers therapeutic advantages. As
`M3 receptors are located not only in the bladder but also
`in the salivary glands and the intestine, this could mean
`that two of the most common side-eCects, dry mouth
`and constipation, will not be avoided.
`Atropine (dL-hyoscyamine)
`is rarely used to treat
`detrusor hyperactivity because of its systemic side-eCects,
`which preclude its use. However,
`in patients with
`
`intravesical atropine may be
`detrusor hyper-reflexia,
`eCective for increasing bladder capacity without causing
`any systemic adverse eCects, as shown in open pilot
`trials [42,43].
`The pharmacologically active antimuscarinic half of
`atropine is l-hyoscyamine. Although widely used, few
`clinical studies are available to evaluate the antimuscar-
`inic activity of l-hyoscyamine sulphate.
`Propantheline bromide is a quaternary ammonium com-
`pound, not selective for muscarinic receptor subtypes,
`which has a low (5–10%) and individually varying
`biological availability [4]. It is usually given in a dose of
`15–30 mg four times daily, but to obtain an optimal
`eCect, individual titration of the dose is necessary, and
`often a higher dosage. Using this approach in 26 patients
`
`© 1999 BJU International 84, 923–947
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 4
`
`

`
`PHARMACOLOGICAL TREATMENT OF URINARY INCONTINENCE
`
`927
`
`Fig. 2. Bladder contraction is mediated by
`the stimulation of muscarinic M2 and M3
`receptors.
`
`with uninhibited detrusor contractions, Blaivas et al.
`[22],
`in an open study, obtained a complete clinical
`response in all patients but one, who did not tolerate
`more than propantheline 15 mg four times daily. The
`range of dosages varied from 7.5 to 60 mg four times
`daily. In contrast, Thu¨ roC et al. [44] comparing the
`eCects oxybutynin 5 mg×3, propantheline 15 mg×3
`and placebo in a randomized, double-blind, multicentre
`trial on the treatment of frequency, urgency and inconti-
`nence related to detrusor hyperactivity (154 patients
`with idiopathic detrusor instability or detrusor hyper-
`reflexia), found no diCerences between the placebo and
`propantheline groups. In another randomized compara-
`tive trial with crossover design (23 women with idio-
`pathic detrusor instability), and with dose titration,
`Holmes et al. [45] found no diCerences in eBcacy between
`oxybutynin and propantheline. Leys [46] found no sig-
`nificant diCerences in the eCect on enuretic children
`comparing propantheline 15–45 mg×4 to placebo.
`Propantheline has a documented eCect on detrusor
`hyperactivity and may,
`in individually titrated doses,
`be clinically useful.
`
`© 1999 BJU International 84, 923–947
`
`Emepronium bromide or carrageenate is a quaternary
`ammonium compound lacking selectivity for muscarinic
`receptor subtypes. It has a low biological availability
`(5–10%) which varies markedly between individuals
`[47]. The dosage must be kept in the range 200 mg 3–4
`times daily or higher. To obtain an optimal eCect,
`individual titration of the drug is necessary; the dose is
`increased until
`incontinence is eliminated or until
`untoward side-eCects preclude further increase. Positive
`eCects in patients with urge incontinence have been
`shown in controlled clinical trials, e.g. [48,49]. Massey
`and Abrams [49] studied the eCects of emepronium
`carrageenate in women with detrusor instability in a
`double-blind, placebo-controlled, randomized crossover
`trial. Dosages were individually titrated; of 72 patients
`entering the study, five were withdrawn during the
`titration phase, 24 were treated with 1200 mg daily and
`43 with 1600/2000 mg daily. There was a dose-
`dependent improvement of both symptoms and mictur-
`ition values. However, some investigators have shown
`emepronium to exert no significant eCects on the bladder
`when administered orally [50].
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 5
`
`

`
`928 K.-E. ANDERSSON et al.
`
`The eCect of emepronium bromide has often been
`attributed to a ganglionic blocking action, and it has
`been suggested that such an eCect would contribute to
`a favourable and selective eCect on the detrusor.
`However, this has never been documented clinically and
`there is no experimental evidence that the drug has a
`selective eCect on the detrusor.
`Emepronium has a documented eCect in detrusor
`hyperactivity and may, in individually titrated doses, be
`clinically useful. Emepronium bromide has been with-
`drawn because of the high incidence of oesophageal/oral
`ulceration. In countries where emepronium is available,
`it is marketed as emepronium carrageenate.
`Trospium chloride is a quaternary ammonium com-
`pound with antimuscarinic actions, but also with eCects
`on ganglia [51]. It has no selectivity for muscarinic
`receptor subtypes. Its biological availability is low, at
`#5% [52]. Several open studies have indicated that the
`drug may be useful in the treatment of detrusor hyper-
`activity [53–55]. In a placebo-controlled, double-blind
`study on patients with detrusor hyper-reflexia [55], the
`drug was given twice daily in a dose of 20 mg over a
`3-week period.
`It
`increased maximum cystometric
`capacity, decreased maximal detrusor pressure and
`increased compliance in the treatment group, whereas
`no eCects were noted in the placebo group. Side-eCects
`were few and comparable in both groups. In a ran-
`domized, double-blind multicentre trial in patients with
`spinal cord injuries and detrusor hyper-reflexia [56],
`trospium and oxybutynin were equally eCective; how-
`ever,
`trospium seemed to have fewer
`side-eCects.
`Trospium chloride has a documented eCect in detrusor
`hyperactivity.
`Tolterodine is a new potent and competitive antagonist
`at muscarinic receptors, intended for the treatment of
`urinary urgency and urge incontinence [57–59]. The
`drug has no selectivity for muscarinic receptor subtypes,
`but still shows some selectivity for the bladder over the
`salivary glands in an animal model [57], and possibly
`in man [60]. Tolterodine has a major active metabolite
`with a similar pharmacological profile [61]. This metab-
`olite significantly contributes to the therapeutic eCect of
`tolterodine [62,63]. Tolterodine is rapidly absorbed and
`has a half-life of 2–3 h, but the eCects on the bladder
`seem to be more long-lasting than could be expected
`from the pharmacokinetic data. The main metabolite
`also has a half-life of 2–3 h [63]. In healthy volunteers,
`orally given tolterodine in a high dose (6.4 mg) had a
`powerful
`inhibitory eCect on micturition and reduced
`stimulated salivation 1 h after administration of the drug
`[60]. However, 5 h after administration, the eCects on
`the urinary bladder were maintained, whereas no sig-
`nificant eCects on salivation could be detected.
`Several randomized, double-blind, placebo-controlled
`
`studies, both on patients with idiopathic detrusor insta-
`bility and detrusor hyper-reflexia, have documented
`a
`significant
`reduction in micturition frequency
`and number of
`incontinence episodes
`[59,64–66].
`Tolterodine seems to be well tolerated when used in the
`dosage range 1–4 mg a day. In a placebo-controlled
`study, comparing tolterodine (2 mg×2) and oxybutynin
`(5 mg×3) in 293 patients with detrusor instability, both
`drugs were found to be equally eCective in reducing the
`frequency of micturition and number of incontinence
`episodes. However, tolterodine appeared to have a better
`eBcacy/tolerability profile [67]. These findings were
`largely confirmed in another study on 240 patients
`with bladder hyperactivity [68]. Tolterodine has a well
`documented eCect in detrusor hyperactivity and the
`side-eCect profile seems acceptable.
`Darifenacin is a highly selective muscarinic M3 receptor
`antagonist [69]. In some animal models, there is a
`marginal selectivity for the urinary bladder over the
`salivary gland [38,70], but the clinical importance of
`this finding has not been established. In a pilot study on
`patients with detrusor instability, the drug was found to
`reduce the total number, maximum amplitude, and
`duration of unstable bladder contractions [71]. The drug
`is being further evaluated clinically for the treatment of
`bladder hyperactivity, but published clinical results do
`not allow an evaluation of its eCects.
`
`Drugs acting on membrane channels
`
`Calcium antagonists
`
`The activation of detrusor muscle, both through muscar-
`inic receptor and NANC pathways, seems to require the
`
`influx of extracellular Ca2+ through Ca2+ channels, as
`well as via mobilization of intracellular Ca2+ [1]. The
`antagonists, blocking l-type Ca2+ channels, and theoreti-
`
`influx of extracellular calcium can be blocked by calcium
`
`inhibiting
`cally this would be an attractive way of
`detrusor hyperactivity [72]. However, there have been
`few clinical studies of the eCects of calcium antagonists
`in patients with detrusor hyperactivity. In an open study,
`Rud et al. [73] found that nifedipine reduced the fre-
`quency and amplitude of unstable detrusor contractions,
`increased bladder capacity and gave symptomatic relief.
`These results could not be confirmed by Laval and
`Lutzeyer [74], who found that nifedipine had no signifi-
`cant eCect on unstable detrusor contractions.
`In a
`double-blind placebo-controlled study, Palmer et al. [75]
`found that flunarizine caused both symptomatic and
`urodynamic improvement in women with urge inconti-
`nence. Unfortunately, their results could not be con-
`firmed by several other investigators [4]. Faustini et al.
`[76] found in an open urodynamic study of patients
`
`© 1999 BJU International 84, 923–947
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 6
`
`

`
`PHARMACOLOGICAL TREATMENT OF URINARY INCONTINENCE
`
`929
`
`with detrusor hyperactivity that diltiazem 60 mg×3 for
`10 days significantly increased bladder capacity, lowered
`bladder pressure and maximum detrusor pressure, and
`raised the threshold of the second sensation of mictur-
`ition. The number of nocturnal micturitions and episodes
`of
`incontinence were decreased. No side-eCects were
`reported.
`instillation of verapamil was found to
`Intravesical
`increase bladder capacity and decrease the degree of
`leakage during cystometry in patients with detrusor
`hyper-reflexia [77]. The eCect was less pronounced in
`patients with non-neurogenic hyperactivity [78].
`Available information does not suggest that systemic
`therapy with calcium antagonists is an eCective way to
`treat detrusor hyperactivity, but controlled clinical trials
`are lacking. However, the possibility that intravesical
`therapy with these drugs could be useful should not be
`ignored, nor that calcium antagonists may enhance the
`eCects of antimuscarinic agents [79].
`
`Potassium-channel openers
`
`Opening of K+ channels and the subsequent eAux of
`K+ will produce hyperpolarization of various smooth
`decrease in Ca2+ influx by reducing the opening prob-
`ability of Ca2+ channels, with subsequent relaxation or
`
`muscles,
`
`including the detrusor [80]. This leads to a
`
`inhibition of contraction. Theoretically, such drugs may
`be active during the filling phase of the bladder, abol-
`ishing bladder hyperactivity with no eCect on normal
`
`bladder contraction. K+-channel openers, such as pinaci-
`
`dil and cromakalim, have been eCective in animal models
`[80], but clinically the eCects have not been encouraging.
`
`The first generation of openers of ATP-sensitive K+-
`
`channels, such as cromakalim and pinacidil, were found
`to be up to 200 times more potent as inhibitors of
`vascular preparations than of detrusor muscle [81,82].
`In clinical trials performed with these drugs, no bladder
`eCects have been found at doses already causing lowering
`of blood pressure [83,84]. However, new drugs with
`KATP-channel opening properties have been described,
`which may be useful for the treatment of bladder hyper-
`activity [85,86].
`
`K+-channel opening is an attractive way of treating
`
`bladder hyperactivity, as it would make it possible to
`eliminate undesired bladder contractions without aCect-
`ing normal micturition. If bladder eCects can be detected
`in man, with no cardiovascular actions, the principle of
`
`K+-channel opening may represent a promising way of
`
`treating bladder hyperactivity. However, at present there
`is no evidence from controlled clinical trials to sug-
`
`gest that K+-channel openers represent a treatment
`
`alternative.
`
`© 1999 BJU International 84, 923–947
`
`Drugs with ‘mixed’ actions
`
`Some drugs used to block bladder hyperactivity have
`been shown to have more than one mechanism of
`action. They all have a more or less pronounced antimus-
`carinic eCect and an often poorly defined ‘direct’ action
`on bladder muscle. For several of
`these drugs,
`the
`antimuscarinic eCects can be detected at much lower
`drug concentrations than the direct action, which may
`
`involve blockade of voltage-operated Ca2+ channels.
`
`Most probably, the clinical eCects of these drugs can be
`explained mainly by an antimuscarinic action. Among
`the drugs with mixed actions was terodiline, which was
`withdrawn from the market because it was suspected to
`cause polymorphic ventricular tachycardia (torsade de
`pointes) in some patients [87,88].
`Oxybutynin has several pharmacological eCects, some
`of which seem diBcult to relate to its eCectiveness in the
`treatment of detrusor hyperactivity.
`It has both an
`antimuscarinic and a direct muscle-relaxant eCect, and
`local anaesthetic actions. The latter eCect may be import-
`ant when the drug is administered intravesically, but
`probably plays no role when it is given orally. In vitro,
`oxybutynin was 500 times weaker as a smooth muscle
`relaxant than as an antimuscarinic agent [89]. Most
`probably, when given systemically, oxybutynin acts
`mainly as an antimuscarinic drug. Oxybutynin has a
`high aBnity for muscarinic receptors in human bladder
`tissue and eCectively blocks carbachol-induced contrac-
`tions [90,91]. The drug was shown to have higher
`aBnity for muscarinic M1 and M3 receptors than for M2
`receptors [92,93], but the clinical significance of this
`is unclear.
`Oxybutynin is a tertiary amine that is well absorbed,
`but undergoes an extensive first-pass metabolism (bio-
`logical availability 6% in healthy volunteers). The plasma
`half-life of the drug is #2 h, but with wide inter-
`individual variation [94,95]. Oxybutynin has an active
`metabolite, N-desethyl oxybutynin, which has pharma-
`cological properties similar to those of the parent com-
`pound [91], but which occurs
`in much higher
`concentrations [95]. Considering this, it seems reason-
`able to assume that the eCect of oral oxybutynin is
`largely exerted by the metabolite. The occurrence of an
`active metabolite may also explain the lack of correlation
`between the plasma concentration of oxybutynin and
`side-eCects in geriatric patients, reported by Ouslander
`et al. [96].
`Several studies, both open and controlled, have shown
`that oxybutynin is eCective in controlling detrusor hyper-
`activity [97]. In a randomized, double-blind, crossover
`trial of 30 patients with detrusor instability, Moisey et al.
`[98] compared oxybutynin 5 mg ×3 with placebo. The
`study was completed by 23 patients; five withdrew
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 7
`
`

`
`930 K.-E. ANDERSSON et al.
`
`because of severe side-eCects. Of the patients who com-
`pleted the trial, 17 (69%) had symptomatic improvement
`and nine had improvement on urodynamic assessment.
`The eCect of oxybutynin in the management of idiopathic
`detrusor instability in women was studied by Cardozo
`et al. [99] in a double-blind, fixed-dose (5 mg) placebo-
`controlled trial. Oxybutynin was significantly better than
`placebo in improving LUTS and urodynamic values.
`However, eight of 20 women receiving oxybutynin
`stopped medication because of side-eCects and of those
`completing active therapy, 80% suCered significant side-
`eCects, e.g. dry mouth or dry skin. This highlights the
`diBculty of conducting double-blind studies with this
`drug because of the severe side-eCects obtained with
`active treatment, which makes it diBcult to blind the
`study. Similar results were shown in other placebo-
`controlled trials of patients with detrusor hyperactivity,
`including hyper-reflexia [44,98,100–105].
`significantly
`Also
`oxybutynin
`7.5–15 mg/day
`improved the quality of life of patients with an overactive
`bladder in a large open multicentre trial. In this study,
`the patients’ compliance was 97% and side-eCects
`(mainly dry mouth) were reported by only 8% of the
`patients [106].
`Holmes et al. [45] compared oxybutynin and propan-
`theline, using a patient-regulated variable-dose approach
`in a randomized, cross-over trial including 23 women
`with detrusor instability. The daily doses of oxybutynin
`were 7.5–30 mg and those of propantheline bromide
`45–145 mg. There were no diCerences in eCectiveness
`between the drugs. On the other hand, Thu¨ roC et al.
`[44], using a fixed-dose protocol and a parallel-group
`design, compared the eCects oxybutynin 5 mg×3, pro-
`pantheline 15 mg×3 and placebo in a randomized,
`double-blind multicentre trial
`including 154 patients
`(149 women, five men) with detrusor hyperactivity
`(including detrusor hyper-reflexia). The mean grade of
`improvement was significantly higher with oxybutynin
`(58%) than with propantheline (45%) or placebo (43%).
`Also, the rate of possible adverse eCects was significantly
`higher for oxybutynin (63%) than for propantheline
`(44%) and placebo (33%).
`Iselin et al. [107] conducted a double-blind, placebo-
`controlled study on 53 patients with BPH to evaluate
`the symptomatic and urodynamic eCects of oxybutynin
`(5 mg×3) on irritative micturitional symptoms during
`the first week after TURP. Compared with placebo,
`oxybutynin significantly decreased frequency, urgency
`and detrusor pressure at first sensation of filling, but had
`no eCect on detrusor instability and did not change the
`maximal bladder capacity. Dryness of the mouth was
`reported in 13% of placebo-treated patients and in 65%
`of those receiving oxybutynin.
`In 75 nursing home residents, Ouslander et al. [108]
`
`found that oxybutynin did not add to the clinical eCec-
`tiveness of prompted voiding in a placebo-controlled,
`double-blind, cross-over trial. In another controlled trial
`in 57 elderly subjects, oxybutynin with bladder training
`was found to be superior to bladder training alone [109].
`Several open studies in patients with spinal cord
`injuries have suggested that oxybutynin, given orally or
`intravesically, can be of therapeutic benefit [110,111].
`Administered intravesically, oxybutynin has in several
`studies been shown to increase bladder capacity and
`produce clinical improvement with few side-eCects, both
`in hyper-reflexia and in other types of bladder hyper-
`activity, and both in children and adults [112–120],
`although adverse eCects may occur [121,122].
`Forms of oxybutynin other than the conventional
`tablet have been introduced; rectal administration [123]
`was reported to have fewer adverse eCects than the
`conventional tablets. A controlled-release preparation,
`administered once daily, was found to be as eCective as
`the conventional tablet given twice daily, and with a
`similar number of adverse events during treatment
`[124]. OROSA oxybutynin, another controlled-release
`preparation given once daily, was tested in an open
`study on 257 patients, and was reported to produce
`fewer side-eCects than conventional forms of oral admin-
`istration [125].
`The therapeutic eCect of oxybutynin on detrusor hyp-
`eractivity is associated with a high incidence of side-
`eCects (up to 80% with oral administration). These are
`typically antimuscarinic
`(dry mouth,
`constipation,
`drowsiness, blurred vision) and are often dose-limiting
`[126,127]. The eCects on the electrocardiogram of
`oxybutynin were studied in elderly patients with urinary
`incontinence [128]; no changes were found. It cannot
`be excluded that the commonly recommended dose of
`5 mg×3 is unnecessarily high in some patients, and
`that a starting dose of 2.5 mg×2 with following dose-
`titration would reduce the number of adverse eCects
`[106,129].
`Oxybutynin has well-documented eBcacy in the treat-
`ment of detrusor hyperactivity and is probably, despite
`its adverse eCect profile, the drug of first choice in
`patients with this disorder.
`Dicyclomine has been described as having both a direct
`relaxant eCect on smooth muscle and an antimuscarinic
`action [130]. Favourable results in detrusor hyperactivity
`have been reported in several studies [131–134]. In 43
`patients with detrusor hyperactivity, Beck et al. [131]
`compared the eCects of three times daily administration
`of dicyclomine 10 mg, propantheline 15 mg or placebo
`for 3 weeks. In the placebo group, 20% were cured or
`improved; the corresponding values for propantheline
`bromide and dicyclomine were 73% and 62%, respect-
`ively. In a preliminary study, Awad et al. [132] reported
`
`© 1999 BJU International 84, 923–947
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1006 - Page 8
`
`

`
`PHARMACOLOGICAL TREATMENT OF URINARY INCONTINENCE
`
`931
`
`that dicyclomine 20 mg×3 caused a resolution or sig-
`nificant improvement of symptoms in 24 of 27 patients
`with uninhibited bladder contractions. Side-eCects were
`few, mainly antimuscarinic, and did not necessitate
`withdrawal from the study. In another preliminary study
`of 14 patients with uninhibited neurogenic bladder,
`Fischer et al. [133] reported that 11 patients showed a
`significant blockade of uninhibited bladder contractions
`when given dicyclomine as a single 20 mg oral dose.
`Even if published experiences of the eCect of dicyclo-
`mine on detrusor hyperactivity are favourable, the drug
`is not widely used, and controlled clinical trials docu-
`menting its eBcacy and side-eCects are scarce.
`Propiverine has been shown to have combined anticho-
`linergic and calcium antagonistic actions [135–138].
`The drug is rapidly absorbed, but has a high first-pass
`metabolism. Several active metabolites are formed [139],
`whose pharmacological characteristics do not seem to
`have been studied in detail. It seems most probable that
`these metabolites contribute to the clinical eCects of
`the drug.
`Propiverine has been shown to have beneficial eCects
`in patients with detrusor hyperactivity in several investi-
`gations
`[140–142] and in children with enuresis
`[143,144]. Most of the studies have been open and are
`preliminary.

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket